shown
patient
cap
medicar
popul
mortal
suggest
pneumonia
may
surrog
marker
sever
underli
comorbid
initi
seri
advers
consequ
patient
lead
eventu
death
despit
avail
differ
guidelin
treatment
option
econom
burden
associ
cap
remain
high
billion
annual
unit
state
alon
although
patient
cap
outpati
greatest
portion
cost
ill
born
admit
hospit
make
decis
admiss
import
one
sever
reason
recent
studi
note
decreas
length
stay
day
patient
cap
potenti
econom
benefit
new
health
care
reform
immin
emphasi
better
health
care
deliveri
costeffect
treatment
pneumonia
assum
greater
signific
sever
challeng
manag
cap
accur
diagnosi
lung
infiltr
decis
site
care
choic
appropri
antibiot
infecti
diseas
societi
america
idsa
american
thorac
societi
at
guidelin
provid
summari
approach
treatment
cap
direct
mainli
toward
primari
care
physician
hospitalist
emerg
medicin
physician
multipl
valid
sever
assess
score
develop
stratifi
patient
accord
risk
death
use
decis
support
tool
guid
siteofcar
decis
emerg
drugresist
organ
particularli
drugresist
streptococcu
pneumonia
drsp
anoth
challeng
diseas
manag
biomark
increasingli
use
distinguish
bacteri
pneumonia
caus
help
reduc
durat
antibiot
therapi
articl
review
recent
advanc
diagnosi
manag
potenti
complic
associ
cap
cap
major
rout
infect
microaspir
previous
colon
oropharynx
inhal
suspend
aerosol
microorgan
mechan
infect
virus
legionella
tuberculosi
interact
host
immun
respons
virul
infect
organ
size
inoculum
determin
whether
patient
develop
pneumonia
defect
cough
mucociliari
clearanc
impair
local
humor
immun
predispos
sever
pneumonia
alcohol
consumpt
smoke
independ
risk
factor
develop
pneumonia
medic
comorbid
chronic
obstruct
pulmonari
diseas
copd
congest
heart
failur
chronic
kidney
diseas
liver
diseas
immun
defici
state
increas
predisposit
develop
cap
recent
use
proton
pump
inhibitor
therapi
start
within
day
identifi
risk
factor
cap
elderli
patient
increas
risk
develop
pneumonia
occur
like
die
younger
individu
although
mani
patient
develop
sever
pneumonia
immun
impair
other
develop
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
consequ
unilater
pneumonia
inabl
local
immun
respons
initi
site
infect
possibl
presenc
genet
variat
immun
respons
common
organ
caus
cap
patient
popul
pneumonia
pneumococcu
pathogen
includ
hemophilu
influenza
particularli
cigarett
smoker
moraxella
catarrhali
staphylococcu
aureu
influenza
recent
form
methicillinresist
aureu
mrsa
virus
includ
influenza
respiratori
syncyti
viru
parainfluenza
epidem
virus
atyp
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
seri
atyp
pathogen
common
includ
admit
icu
account
identifi
pathogen
addit
mani
investig
document
atyp
pathogen
may
coexist
bacteri
pathogen
account
presenc
patient
cap
serolog
test
use
gramneg
bacteria
pseudomona
aeruginosa
klebsiella
pneumonia
escherichia
coli
enterobact
spp
serratia
spp
proteu
spp
causal
agent
patient
cap
may
common
patient
develop
pneumonia
hospit
hcap
risk
factor
gramneg
bacteria
associ
sever
cap
k
pneumonia
note
independ
risk
factor
mortal
sever
cap
one
studi
korea
multivari
analysi
risk
factor
associ
gramneg
cap
septic
shock
odd
ratio
cardiac
diseas
smoke
hyponatremia
dyspnea
emphas
associ
organ
sever
ill
enterobact
cap
behav
like
hospitalacquir
pneumonia
associ
prolong
mechan
ventil
delay
initi
antibiot
longer
icu
stay
risk
factor
communityacquir
p
aeruginosa
pneumonia
includ
bronchiectasi
immunocompromis
state
use
multipl
cours
antibiot
prolong
glucocorticoid
patient
copd
recent
hospit
anaerob
organ
consid
aspir
suspect
influenza
common
viral
caus
cap
season
variat
frequenc
primari
influenza
pneumonia
tend
caus
sever
pneumonia
either
caus
viru
result
secondari
bacteri
infect
pneumococcu
aureu
h
influenza
highrisk
patient
includ
chronic
heart
lung
diseas
diabet
immunosuppress
hemoglobinopathi
renal
diseas
otherwis
healthi
individu
year
age
virus
caus
cap
includ
parainfluenza
viru
respiratori
syncyti
viru
rsv
human
metapneumoviru
sever
acut
respiratori
syndrom
viru
varicella
hantaviru
adenoviru
mani
patient
viral
infect
part
mix
infect
often
bacteri
pathogen
emerg
drsp
communityacquir
mrsa
matter
concern
complic
empir
therapi
choic
patient
cap
drsp
seen
often
patient
older
year
age
histori
alcohol
antibiot
therapi
within
month
multipl
medic
comorbid
condit
exposur
children
day
care
immunecompromis
state
communityassoci
mrsa
camrsa
pneumonia
occur
patient
prior
health
care
exposur
usual
influenza
may
lead
sever
necrot
pneumonia
although
milder
form
ill
also
report
patient
sever
ill
organ
may
produc
varieti
exotoxin
includ
pantonvalentin
leukocidin
pvl
may
contribut
lung
necrosi
multidrug
resist
report
camrsa
strain
gener
organ
drug
sensit
hospitalacquir
counterpart
less
common
caus
cap
includ
mycobacterium
tuberculosi
coxiella
burnetii
q
fever
burkholderia
pseudomallei
melioidosi
chlamydophila
psittaci
psittacosi
endem
fungi
histoplasmosi
coccidioidomycosi
blastomycosi
pasteurella
multocida
bacillu
anthraci
actinomyc
isra
francisella
tularensi
tularemia
nocardia
spp
organ
includ
differenti
diagnosi
evalu
patient
cap
depend
presenc
specif
risk
factor
note
clinic
histori
patient
cap
usual
present
acut
ill
day
durat
intact
immun
respons
system
respiratori
symptom
cough
dyspnea
fever
pleurit
chest
pain
predomin
fever
chill
sensit
dyspnea
sensit
diagnosi
cap
wherea
purul
sputum
sensit
hemoptysi
suggest
necrot
infect
lung
abscess
tuberculosi
gramneg
pneumonia
also
common
find
even
patient
bronchiti
patient
diseas
ageassoci
impair
immun
respons
clinic
present
may
subtl
involv
primarili
nonrespiratori
find
elderli
chest
pain
cough
may
absent
earli
cours
diseas
fever
confus
may
symptom
complaint
lethargi
fall
poor
oral
intak
decompens
chronic
ill
could
also
occur
patient
comorbid
condit
among
elderli
good
histori
physic
examin
essenti
determin
possibl
causal
agent
assess
sever
ill
turn
help
manag
risk
factor
hcap
hospit
antibiot
therapi
past
day
resid
longterm
care
facil
chronic
dialysi
outpati
wound
care
home
infus
therapi
need
identifi
patient
risk
drugresist
gramneg
organ
aureu
histori
identifi
risk
factor
drsp
gramneg
organ
discuss
earlier
also
import
elicit
recent
travel
histori
exposur
bird
bat
farm
anim
rabbit
tabl
physic
examin
patient
may
tachypnea
tachycardia
crackl
bronchial
breath
sound
find
pleural
effus
clinician
pay
attent
clue
rel
bradycardia
relat
fever
seen
infect
caus
agent
like
legionella
chlamydophila
mycoplasma
mycoplasma
also
caus
cervic
lymphadenopathi
arthralgia
bullou
myring
poor
outcom
note
patient
respiratori
rate
greater
breathsmin
diastol
blood
pressur
less
mm
hg
systol
blood
pressur
less
mm
hg
heart
rate
greater
beatsmin
temperatur
less
c
greater
c
clinic
find
use
determin
risk
death
incorpor
prognost
score
use
pneumonia
sever
index
psi
criteria
modif
british
thorac
societi
score
system
tool
discuss
later
rais
clinic
suspicion
combin
symptom
sign
accur
diagnos
pneumonia
clinic
set
definit
diagnosi
requir
chest
radiograph
clinic
diagnosi
overal
sensit
rang
specif
therefor
whenev
suspicion
cap
chest
radiograph
obtain
corrobor
physic
find
certain
chest
radiograph
find
also
suggest
sever
ill
includ
presenc
multilobar
infiltr
rapid
progress
infiltr
pleural
effus
find
necrot
pneumonia
outpati
set
extens
diagnost
test
routin
perform
result
nonspecif
antibiot
treatment
initi
nair
niederman
empir
even
inpati
valu
diagnost
test
limit
outcom
compar
use
pathogendirect
therapi
compar
empir
therapi
limit
benefit
test
one
prospect
studi
patient
netherland
pathogen
identifi
case
adequ
sputum
sampl
obtain
patient
gram
stain
diagnost
confirm
posit
sputum
urin
pneumococc
antigen
posit
case
blood
cultur
posit
bronchoscop
sampl
ad
benefit
diagnost
yield
sputum
could
expector
studi
specif
causal
diagnosi
obtain
less
patient
cap
even
extens
diagnost
test
major
focu
laboratori
test
assess
sever
ill
allow
earli
identif
presenc
pneumon
complic
white
blood
cell
count
may
normal
admiss
leukopenia
seen
patient
overwhelm
pneumococc
pneumonia
sepsi
pneumonia
caus
gramneg
organ
thrombocytosi
thrombocytopenia
associ
wors
mortal
patient
admit
cap
hyponatremia
meql
also
associ
poor
outcom
present
admiss
patient
cap
idsaat
guidelin
recommend
test
patient
pneumonia
tabl
radiograph
evid
lung
infiltr
provid
sensit
specif
confirm
communityacquir
pneumonia
chest
radiograph
may
show
area
consolid
pleural
effus
lung
abscess
necrot
pneumonia
multilobar
ill
may
help
pattern
recognit
diseas
process
h
influenza
peribronchi
distribut
bronchopneumonia
pneumonia
infect
either
lobar
consolid
bronchopneumonia
atyp
pathogen
may
alveolar
interstiti
pattern
aspir
commonli
involv
superior
segment
right
lower
lobe
posterior
segment
right
upper
lobe
hematogen
dissemin
follow
distribut
blood
flow
may
lead
bilater
nodular
infiltr
cavit
necrot
pneumonia
suggest
infect
anaerob
gramneg
bacteria
aureu
includ
mrsa
locul
effus
rule
decubitu
film
comput
tomographi
ct
chest
ultrasound
increasingli
use
assess
size
identifi
safe
site
sampl
pleural
fluid
use
chest
radiographi
suboptim
patient
earli
infect
dehydr
sever
granulocytopenia
structur
chang
bullou
emphysema
obes
patient
reason
repeat
followup
radiograph
hour
patient
neg
initi
find
clinic
sign
pneumonia
may
interobserv
variabl
chest
radiograph
interpret
pneumonia
studi
compar
read
least
radiologist
posit
agreement
less
frequent
neg
agreement
ct
better
sensit
diagnos
infiltr
chest
radiographi
routin
use
lack
evid
use
ct
scan
improv
outcom
sputum
sent
gram
stain
cultur
start
therapi
primarili
patient
suspect
infect
drugresist
unusu
pathogen
good
specimen
contain
squamou
epitheli
cell
polymorphonuclear
cell
per
low
per
field
gram
stain
pattern
sputum
help
tailor
antibiot
particularli
show
pathogen
would
treat
routin
clump
gramposit
cocci
suggest
aureu
sensit
identifi
pneumonia
specif
greater
less
like
aureu
gramneg
pneumonia
absenc
organ
gram
stain
good
sputum
sampl
test
valuabl
posit
neg
routin
cultur
expector
sputum
use
absenc
inform
gram
stain
use
realtim
polymeras
chain
reaction
test
sputum
sampl
shown
cultur
obtain
intub
patient
collect
endotrach
aspir
posit
blood
pleural
cultur
seen
less
patient
pneumonia
present
help
establish
diagnosi
posit
cultur
pneumonia
idsaat
guidelin
recommend
blood
cultur
test
patient
admit
icu
multipl
risk
factor
includ
activ
alcohol
abus
liver
diseas
cavitatori
lung
diseas
asplenia
leukopenia
pleural
effus
recommend
base
part
data
medicar
patient
show
trueposit
blood
cultur
associ
previou
antibiot
underli
liver
diseas
systol
blood
pressur
less
mm
hg
fever
less
c
greater
c
puls
greater
beat
min
blood
urea
nitrogen
greater
mmoll
mgdl
serum
sodium
less
mmol
leukocyt
count
less
greater
cell
ml
diagnost
yield
blood
cultur
increas
patient
risk
factor
receiv
antibiot
blood
collect
urinari
antigen
test
uat
commerci
avail
detect
capsular
polysaccharid
pneumonia
l
pneumophilia
serogroup
pneumococc
urinari
antigen
test
sensit
specif
degre
posit
correl
psi
pneumonia
falseposit
test
occur
patient
cap
pneumococcu
within
previou
month
uat
legionella
sensit
specif
detect
infect
serogroup
far
commonest
speci
infect
human
howev
detect
type
legionella
neg
find
rule
infect
one
studi
use
uat
legionella
increas
time
lead
diagnos
serogroup
infect
decreas
mortal
legionella
suggest
urinari
antigen
test
find
milder
ill
recogn
previous
although
one
prospect
studi
episod
cap
spain
found
pneumonia
diagnos
urinari
antigen
test
help
physician
optim
antibiot
choic
gener
remain
uncertain
whether
posit
result
urinari
antigen
test
chang
cap
manag
whether
primarili
epidemiolog
interest
serolog
test
question
import
initi
set
use
epidemiolog
diagnosi
agent
readili
cultur
although
result
gener
avail
week
requir
collect
acut
convalesc
serum
sampl
diagnosi
pathogen
base
acut
convalesc
blood
serolog
show
fourfold
increas
immunoglobulin
ig
g
obtain
week
apart
appli
c
pneumonia
c
psittaci
q
fever
pneumonia
ig
antibodi
start
increas
acut
phase
use
earli
cours
diseas
cold
agglutinin
sometim
present
patient
pneumonia
nucleic
acid
amplif
test
provid
rapid
test
result
cap
atyp
agent
virus
mycoplasma
chlamydophila
legionella
polymeras
chain
reaction
pcr
assay
wide
use
detect
influenza
viru
recent
epidem
direct
immunofluoresc
enzym
immunoassay
avail
detect
viral
antigen
like
influenza
rsv
adenoviru
parainfluenza
virus
use
pcr
assay
manag
cap
proven
concern
method
sensit
respiratori
sampl
posit
distinguish
colon
infect
unless
presenc
specif
pathogen
diagnost
infect
tuberculosi
howev
test
may
valuabl
neg
absenc
suspect
pathogen
pcr
may
permit
focus
antibiot
therapi
approach
sever
newer
biomark
develop
midregion
proadrenomedullin
midregion
proatrial
natriuret
peptid
proargininvasopressin
procalcitonin
pct
creactiv
protein
crp
identifi
patient
bacteri
infect
defin
prognosi
cap
one
recent
studi
cardiac
biomark
midregion
proadrenomedullin
better
predictor
mortal
inflammatori
biomark
pct
studi
biomark
correl
diseas
sever
mortal
help
causal
diagnosi
anoth
prospect
studi
evalu
relationship
biomark
icu
admiss
inflammatori
biomark
help
identifi
patient
need
intens
care
monitor
includ
requir
delay
icu
admiss
inflammatori
biomark
studi
extens
crp
pct
acutephas
reactant
primarili
produc
liver
presenc
bacteri
infect
viral
ill
crp
may
identifi
patient
acut
respiratori
symptom
infecti
pneumonia
level
higher
patient
requir
hospit
pneumococc
legionella
infect
pct
hormokin
produc
respons
microbi
toxin
certain
host
respons
associ
bacteri
infect
inhibit
viralrel
cytokin
serum
level
tend
high
patient
cap
benefit
antibiot
therapi
increas
risk
death
cap
serial
measur
serum
level
also
use
defin
antibiot
safe
stop
presenc
cap
one
studi
patient
radiograph
infiltr
suspect
cap
initi
antibiot
durat
therapi
determin
random
patient
manag
algorithm
dictat
serial
pct
measur
versu
manag
clinic
assess
pctguid
group
significantli
fewer
antibiot
prescript
admiss
less
antibiot
usag
durat
therapi
reduc
day
similar
clinic
success
one
import
decis
manag
pneumonia
assess
sever
diseas
use
predict
mortal
risk
may
nair
niederman
surrog
measur
defin
site
care
outpati
hospit
ward
icu
proper
siteofcar
decis
impact
mortal
sever
studi
show
delay
admiss
icu
lead
poor
outcom
wide
use
prognost
score
system
psi
score
clinic
practic
psi
wide
use
complex
difficult
calcul
score
addit
gener
score
tool
evalu
design
identifi
need
icu
admiss
includ
idsaat
criteria
sever
cap
australian
method
call
smartcop
design
predict
need
intens
respiratori
vasopressor
support
predict
rule
avail
clinic
applic
vari
wide
psi
develop
identifi
patient
low
risk
die
could
safe
discharg
home
receiv
outpati
treatment
psi
stratifi
patient
categori
base
mortal
use
score
system
base
factor
includ
demograph
characterist
coexist
ill
physic
examin
find
laboratori
measur
radiograph
find
patient
class
iv
mortal
risk
v
risk
death
day
usual
admit
hospit
often
icu
lowrisk
class
ii
often
treat
outpati
wherea
clinic
judgment
whether
class
iii
hospit
psi
score
includ
age
import
determin
point
score
henc
overestim
sever
ill
elderli
comorbid
one
studi
patient
psi
class
v
approxim
need
icu
admiss
tend
individu
score
point
base
acut
ill
featur
age
comorbid
ill
factor
contrast
psi
may
underestim
sever
ill
young
patient
without
comorbid
ill
especi
vital
sign
abnorm
slightli
less
cutoff
use
score
system
particular
problem
recent
influenza
epidem
involv
primarili
younger
popul
psi
score
valuabl
defin
need
icu
admiss
score
british
thorac
societi
easi
score
system
use
score
defin
point
presenc
confus
blood
urea
nitrogen
greater
moll
mgdl
respiratori
rate
breathsmin
greater
systol
blood
pressur
less
mm
hg
diastol
blood
pressur
greater
mm
hg
age
year
older
patient
criteria
high
enough
risk
death
probabl
admit
hospit
point
consid
icu
admiss
modif
tool
without
laboratori
measur
blood
urea
nitrogen
also
found
similarli
accur
limit
approach
focu
assess
clinic
paramet
vital
sign
without
measur
oxygen
serial
measur
sever
ill
initi
hospit
admiss
evalu
presenc
comorbid
ill
decompens
baselin
serum
biomark
use
supplement
data
obtain
prognost
score
data
german
compet
network
studi
commun
acquir
pneumonia
capnetz
studi
group
show
new
biomark
good
predictor
shortterm
longterm
allcaus
mortal
correl
score
studi
low
level
pct
abl
defin
patient
low
risk
death
regardless
find
use
sever
score
huang
colleagu
well
kruger
colleagu
found
even
patient
identifi
high
risk
use
psi
low
pct
valu
predict
low
chanc
die
sever
cap
score
system
also
use
help
defin
patient
need
icu
care
identifi
sever
ill
idsaat
guidelin
piro
predisposit
insult
respons
organ
dysfunct
score
system
develop
help
defin
mortal
risk
patient
sever
pneumonia
accord
idsaat
guidelin
sever
cap
present
patient
need
invas
mechan
ventil
requir
vasopressor
minor
criteria
list
later
liapak
colleagu
found
patient
meet
major
criteria
need
icu
admiss
patient
minor
criteria
present
increas
mortal
risk
regardless
mani
criteria
met
recent
brown
colleagu
found
posit
neg
predict
valu
minor
criteria
exceed
criteria
use
defin
need
icu
admiss
rather
criteria
piro
score
calcul
within
hour
icu
admiss
point
given
variabl
comorbid
copd
immunocompromis
age
greater
year
multilobar
opac
chest
radiograph
shock
sever
hypoxemia
acut
renal
failur
bacteremia
acut
respiratori
distress
syndrom
maximum
score
achiev
patient
stratifi
level
risk
low
point
b
mild
point
c
high
point
high
point
piro
score
perform
well
mortal
predict
tool
patient
cap
requir
icu
admiss
better
perform
apach
ii
idsa
at
criteria
smartcop
tool
develop
identifi
need
intens
respiratori
vasopressor
support
irv
rather
specif
siteofcar
decis
tool
use
complex
score
system
follow
valu
low
systol
blood
pressur
mm
hg
point
multilobar
pneumonia
point
low
albumin
level
gdl
point
high
respiratori
rate
breathsmin
point
tachycardia
beatsmin
point
confus
point
poor
oxygen
point
low
arteri
ph
point
method
use
find
patient
score
point
identifi
need
irv
specif
wherea
psi
perform
well
algorithm
decis
site
care
base
score
system
treatment
strategi
provid
later
fig
earli
diagnosi
time
administr
antibiot
associ
improv
outcom
patient
cap
although
administr
therapi
within
hour
arriv
hospit
reduc
mortal
import
use
antibiot
diagnosi
certain
indiscrimin
use
antibiot
absenc
radiograph
pneumonia
limit
benefit
real
risk
communityacquir
pneumonia
antibioticassoci
advers
event
includ
druginduc
infecti
diarrhea
accord
idsaat
guidelin
first
dose
antibiot
given
emerg
depart
prefer
within
hour
arriv
time
period
specifi
diagnost
test
rapidli
identifi
causal
pathogen
patient
cap
initi
therapi
empir
base
epidemiolog
assess
patient
risk
factor
specif
pathogen
assess
requir
care
histori
patient
comorbid
recent
antibiot
therapi
histori
within
past
month
identif
pathogenspecif
risk
factor
see
tabl
box
idsaat
guidelin
recommend
outpati
treatment
macrolid
doxycyclin
previous
healthi
adult
patient
risk
factor
drsp
patient
risk
factor
drsp
respiratori
fluoroquinolon
blactam
antibiot
plu
macrolid
doxycyclin
recommend
choos
option
import
take
histori
antibiot
usag
past
month
use
agent
differ
recent
use
recent
therapi
may
predispos
pneumococc
resist
agent
use
render
therapi
less
effect
patient
admit
hospit
icu
intraven
respiratori
fluoroquinolon
blactam
plu
macrolid
use
mention
earlier
choic
influenc
histori
antibiot
use
past
month
use
agent
differ
class
possibl
doxycyclin
patient
allerg
penicillin
respiratori
fluoroquinolon
plu
aztreonam
communityacquir
mrsa
suspect
vancomycin
possibl
clindamycin
linezolid
alon
ad
regimen
pseudomona
suspect
blactam
activ
p
aeruginosa
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
blactam
activ
pseudomona
plu
aminoglycosid
azithromycin
nonpseudomon
respiratori
fluoroquinolon
moxifloxacin
altern
macrolid
ertapenem
altern
blactam
agent
cefotaxim
ceftriaxon
ampicillinsulbactam
consid
patient
risk
factor
infect
gramneg
pathogen
p
aeruginosa
patient
cap
routin
therapi
direct
pneumococcu
atyp
pathogen
plu
organ
dictat
specif
risk
factor
routin
coverag
atyp
pathogen
base
outcom
studi
show
addit
macrolid
blactam
use
quinolon
alon
lead
better
outcom
blactam
monotherapi
addit
studi
shown
high
frequenc
atyp
pathogen
coinfect
patient
bacteri
cap
current
cap
guidelin
recommend
monotherapi
agent
includ
quinolon
patient
sever
cap
admit
icu
patient
bacteremia
pneumococc
atyp
pathogen
coverag
macrolid
monotherapi
combin
improv
mortal
compar
treatment
regimen
quinolon
particularli
quinolon
monotherapi
combin
therapi
blactam
macrolid
surviv
advantag
compar
quinolon
alon
patient
icu
prospect
studi
compar
quinolon
monotherapi
blactamquinolon
combin
therapi
monotherapi
arm
effect
addit
patient
pneumococc
bacteremia
especi
sever
ill
use
dual
therapi
usual
ad
macrolid
blactam
associ
better
outcom
monotherapi
impli
benefit
atyp
pathogen
coverag
antiinflammatori
effect
macrolid
prospect
studi
rodriguez
colleagu
patient
cap
shock
requir
vasopressor
combin
therapi
either
blactam
macrolid
blactam
quinolon
surviv
advantag
compar
monotherapi
blactam
quinolon
alon
base
data
patient
icu
intraven
blactam
plu
either
macrolid
respiratori
fluoroquinolon
recommend
patient
without
pseudomon
risk
factor
patient
risk
factor
pseudomon
infect
antipseudomon
blactam
combin
either
levofloxacin
ciprofloxacin
antipseudomon
blactam
combin
aminoglycosid
either
azithromycin
respiratori
quinolon
patient
allerg
penicillin
respiratori
fluoroquinolon
use
aztreonam
altern
regimen
camrsa
suspect
vancomycin
linezolid
ad
recommend
agent
howev
may
necessari
add
antitoxin
produc
agent
part
ill
caus
camrsa
mediat
bacteri
exotoxin
product
stop
toxin
product
may
necessari
add
clindamycin
vancomycin
use
linezolid
alon
outpati
mildtomoder
cap
treat
day
fewer
oral
antibiot
therapi
stop
afebril
clinic
featur
pneumonia
resolv
cough
dyspnea
sputum
product
inpati
antibiot
switch
intraven
oral
patient
afebril
least
occas
hour
apart
abl
take
food
mouth
clinic
sign
improv
paramet
cough
dyspnea
sputum
product
oxygen
vital
sign
abnorm
usual
happen
second
third
hospit
day
switch
oral
antibiot
also
done
bacterem
patient
although
may
take
longer
patient
reach
clinic
stabil
compar
nonbacterem
patient
use
pct
guid
decid
durat
antibiot
use
support
clinic
trial
data
durat
therapi
minimum
day
provid
patient
afebril
hour
sign
communityacquir
pneumonia
extrapulmonari
infect
correct
therapi
use
initi
organ
identifi
aureu
p
aeruginosa
appropri
antibiot
treatment
case
cap
resolv
without
complic
howev
treat
physician
alert
potenti
complic
detect
earli
lead
advers
outcom
patient
respond
well
therapi
immedi
followup
radiograph
need
imag
done
week
discharg
defin
new
radiograph
baselin
patient
chest
radiograph
usual
clear
within
week
especi
patient
younger
year
without
underli
pulmonari
diseas
bacteremia
howev
resolut
may
delay
week
longer
older
individu
underli
lung
diseas
bacteremia
patient
lack
respons
clinic
deterior
despit
antibiot
therapi
idsaat
guidelin
defin
earli
failur
progress
pneumonia
clinic
deterior
occur
first
hour
therapi
usual
respiratori
failur
septic
shock
consequ
inappropri
antibiot
therapi
incorrect
initi
diagnosi
later
failur
nonrespons
often
caus
nosocomi
infect
diseaserel
therapi
complic
noninfecti
process
eg
pulmonari
embol
inflammatori
lung
diseas
patient
persist
fever
worsen
dyspnea
unresolv
pneumonia
symptom
continu
debil
repeat
radiograph
done
focus
broad
differenti
diagnosi
includ
therapi
unusu
drugresist
pathogen
tuberculosi
endem
fungu
zoonosi
pneumon
complic
empyema
antibiot
complic
druginduc
coliti
nonpneumon
diagnosi
inflammatori
lung
diseas
malign
diagnost
test
includ
chest
ct
scan
bronchoscopi
case
open
lung
biopsi
organ
pneumonia
complic
viral
lung
infect
process
character
fibroblast
prolifer
diagnos
combin
radiograph
find
bronchoscop
lung
biopsi
absenc
ongo
infect
often
manag
therapeut
trial
steroid
definit
investig
open
lung
biopsi
parapneumon
effus
empyema
complic
lead
appar
treatment
failur
chest
radiograph
show
effus
sampl
low
pleural
fluid
ph
present
previous
healthi
chronic
ill
organ
present
chest
tube
drainag
prolong
antibiot
therapi
requir
connect
pleural
space
lung
develop
result
bronchopleur
fistula
caus
eros
lung
infect
pleural
surfac
bronchopleur
fistula
initi
treat
conserv
antibiot
chest
tube
sometim
requir
surgic
repair
local
bronchiectasi
longterm
sequela
cap
result
injuri
dilat
bronchu
seen
ct
scan
chest
patient
present
chronic
product
sputum
recurr
infect
area
treatment
postur
drainag
antibiot
exacerb
bronchodil
coexist
airflow
obstruct
recurr
pneumonia
occur
clinic
radiograph
resolut
pneumonia
present
whether
differ
area
origin
infect
determin
area
anatom
problem
obstruct
tumor
foreign
bodi
need
consid
wherea
anoth
site
may
consequ
gener
immun
impair
risk
problem
higher
elderli
histori
alcohol
smoker
underli
system
immun
defici
rule
measur
quantit
ig
level
detail
discuss
prevent
beyond
scope
articl
idsaat
guidelin
mainstay
prevent
pneumococc
influenza
vaccin
atrisk
individu
provis
smoke
cessat
inform
smoke
cigarett
time
pneumonia
onset
influenza
vaccin
recommend
appropri
season
person
age
year
older
specif
risk
factor
includ
pregnant
women
chronic
heart
lung
metabol
hematolog
immunecompromis
ill
pneumococc
polysaccharid
vaccin
given
patient
age
year
older
younger
patient
chronic
heart
lung
diseas
asplenia
diabet
mellitu
resid
longterm
care
facil
one
revaccin
year
given
either
poor
immun
respons
age
year
first
immun
age
year
guidelin
also
perform
measur
hospit
patient
vaccin
given
discharg
patient
admit
cap
